Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 1.30
- Piotroski Score 4.00
- Grade Buy
- Symbol (PROF)
- Company Profound Medical Corp.
- Price $7.89
- Changes Percentage (-1.56%)
- Change -$0.13
- Day Low $7.77
- Day High $8.00
- Year High $11.69
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain relief associated with metastases in bone, as well as non-invasive treatment of uterine fibroids. Profound Medical Corp. is headquartered in Mississauga, Canada.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/06/2025
- Fiscal Year End N/A
- Average Stock Price Target $14.25
- High Stock Price Target $16.50
- Low Stock Price Target $12.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.29
- Trailing P/E Ratio -6.34
- Forward P/E Ratio -6.34
- P/E Growth -6.34
- Net Income $-28,569,000
Income Statement
Quarterly
Annual
Latest News of PROF
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
The past year for Kontron (ETR:SANT) investors has not been profitable
Investing in index funds is a simple way to benefit from a rising market. While individual stocks offer higher profits, there's also a risk of under-performance. Kontron AG's stock has shown short-ter...
By Yahoo! Finance | 20 hours ago -
Xiaomi's Third-Quarter Net Profit Likely Fell Despite Higher Revenue -- Earnings Preview
Xiaomi is expected to announce third-quarter results with predicted net profit of 4.47 billion yuan, down 8.2%, and revenue of 89.66 billion yuan. Its electric vehicle sales have bolstered stock perfo...
By MarketWatch | 1 day ago -
Everest Medicines (SEHK:1952) Eyes Growth with EVER001 Launch and AI Investments Despite Profitability Concerns
Everest Medicines (SEHK:1952) anticipates a 37.2% annual revenue growth driven by EVER001 introduction. Challenges include unprofitability and cost management issues....
By Yahoo! Finance | 1 day ago
